Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for OmniAb, Inc. (OABI : NSDQ)

• Company Description    OmniAb Inc. discovery platform provides pharmaceutical industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. OmniAb Inc., formerly known as Avista Public Acquisition Corp. II, is based in SAN DIEGO. Number of Employees: 89

• Price / Volume Information    Yesterday's Closing Price: $4.07 Daily Weekly Monthly 20 Day Moving Average: 2,578,308 shares Shares Outstanding: 144.78 (millions) Market Capitalization: $589.27 (millions) Beta: 0.62 52 Week High: $5.43 52 Week Low: $1.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 18.66% 20.86% 12 Week 73.93% 70.38% Year To Date 120.00% 92.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5980 Horton Street Suite 600 - Emeryville,CA 94608 USA ph: 510-250-7800 fax: - investors@omniab.com http://www.omniab.com

• General Corporate Information    Officers Matthew W. Foehr - President and Chief Executive Officer John L. Higgins - Chairman Kurt Gustafson - Executive Vice President and Chief Financial Offic Carolyn R. Bertozzi - Director Jennifer Cochran - Director Peer Information OmniAb, Inc. (GSAC) OmniAb, Inc. (CASIF) OmniAb, Inc. (ALCD.) OmniAb, Inc. (OMNN) OmniAb, Inc. (CGPI.) OmniAb, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 68218J103 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/03/26 Share - Related Items Shares Outstanding: 144.78 Most Recent Split Date: (:1) Beta: 0.62 Market Capitalization: $589.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.35 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.26 Price/Cash Flow: - Price / Sales: 15.32 EPS Growth vs. Year Ago Period: 66.67% vs. Previous Quarter: 16.67% Sales Growth vs. Year Ago Period: 244.24% vs. Previous Quarter: -7.01% ROE 06/30/26 - -16.59 03/31/26 - -20.31 12/31/25 - -23.99 ROA 06/30/26 - -14.82 03/31/26 - -18.10 12/31/25 - -21.37 Current Ratio 06/30/26 - 4.80 03/31/26 - 4.80 12/31/25 - 4.02 Quick Ratio 06/30/26 - 4.80 03/31/26 - 4.80 12/31/25 - 4.02 Operating Margin 06/30/26 - -115.12 03/31/26 - -187.59 12/31/25 - -347.04 Net Margin 06/30/26 - -115.12 03/31/26 - -187.59 12/31/25 - -347.04 Pre-Tax Margin 06/30/26 - -118.86 03/31/26 - -190.93 12/31/25 - -355.16 Book Value 06/30/26 - 1.80 03/31/26 - 1.81 12/31/25 - 1.85 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©